Wells Fargo’s Atossa Therapeutics ATOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.56K | Buy |
296
+290
| +4,833% | +$1.84K | ﹤0.01% | 6280 |
|
|
2025
Q4 | $49 | Hold |
6
| – | – | ﹤0.01% | 6522 |
|
|
2025
Q3 | $72 | Sell |
6
-30
| -83% | -$371 | ﹤0.01% | 6429 |
|
|
2025
Q2 | $450 | Sell |
36
-4,867
| -99% | -$58.2K | ﹤0.01% | 6383 |
|
|
2025
Q1 | $49.5K | Buy |
4,903
+122
| +3% | +$1.48K | ﹤0.01% | 5400 |
|
|
2024
Q4 | $67.7K | Buy |
4,781
+1,123
| +31% | +$21.9K | ﹤0.01% | 5392 |
|
|
2024
Q3 | $83.4K | Buy |
3,658
+120
| +3% | +$2.42K | ﹤0.01% | 5123 |
|
|
2024
Q2 | $63.1K | Buy |
3,538
+3,477
| +5,700% | +$76.9K | ﹤0.01% | 5200 |
|
|
2024
Q1 | $1.66K | Hold |
61
| – | – | ﹤0.01% | 6065 |
|
|
2023
Q4 | $801 | Buy |
61
+3
| +5% | +$32 | ﹤0.01% | 6281 |
|
|
2023
Q3 | $639 | Sell |
58
-279
| -83% | -$4.05K | ﹤0.01% | 6311 |
|
|
2023
Q2 | $6.37K | Buy |
337
+2
| +0.6% | +$24 | ﹤0.01% | 6031 |
|
|
2023
Q1 | $3.64K | Buy |
335
+281
| +520% | +$3.13K | ﹤0.01% | 6124 |
|
|
2022
Q4 | $429 | Buy |
54
+1
| +2% | +$11 | ﹤0.01% | 6426 |
|
|
2022
Q3 | $1K | Sell |
53
-3
| -5% | -$44 | ﹤0.01% | 6270 |
|
|
2022
Q2 | $1K | Sell |
56
-1,607
| -97% | -$25.3K | ﹤0.01% | 6460 |
|
|
2022
Q1 | $32K | Sell |
1,663
-2,714
| -62% | -$55.1K | ﹤0.01% | 5839 |
|
|
2021
Q4 | $105K | Buy |
+4,377
| New | +$160K | ﹤0.01% | 5601 |
|
|
2021
Q3 | – | Sell |
-78
| Closed | -$7K | – | 6949 |
|
|
2021
Q2 | $7K | Buy |
78
+14
| +22% | +$741 | ﹤0.01% | 6227 |
|
|
2021
Q1 | $2K | Buy |
64
+59
| +1,180% | +$2.16K | ﹤0.01% | 6622 |
|
|
2020
Q4 | $0 | Buy |
5
+1
| +25% | +$23 | ﹤0.01% | 6473 |
|
|
2020
Q3 | $0 | Hold |
4
| – | – | ﹤0.01% | 6315 |
|
|
2020
Q2 | $0 | Hold |
4
| – | – | ﹤0.01% | 6270 |
|
|
2020
Q1 | $0 | Buy |
+4
| New | +$79 | ﹤0.01% | 6179 |
|
|
2018
Q4 | – | Sell |
-6
| Closed | – | – | 6376 |
|
|
2018
Q3 | $0 | Hold |
6
| – | – | ﹤0.01% | 6379 |
|
|
2018
Q2 | $0 | Hold |
6
| – | – | ﹤0.01% | 6310 |
|
|
2018
Q1 | $0 | Hold |
6
| – | – | ﹤0.01% | 6349 |
|
|
2017
Q4 | $0 | Sell |
6
-7
| -54% | -$509 | ﹤0.01% | 6329 |
|
|
2017
Q3 | $1K | Hold |
13
| – | – | ﹤0.01% | 6204 |
|
|
2017
Q2 | $1K | Hold |
13
| – | – | ﹤0.01% | 6095 |
|
|
2017
Q1 | $2K | Hold |
13
| – | – | ﹤0.01% | 6151 |
|
|
2016
Q4 | $3K | Buy |
13
+4
| +44% | +$1.25K | ﹤0.01% | 6029 |
|
|
2016
Q3 | $3K | Sell |
9
-2
| -18% | -$1.2K | ﹤0.01% | 5989 |
|
|
2016
Q2 | $8K | Buy |
11
+2
| +22% | +$1.62K | ﹤0.01% | 5720 |
|
|
2016
Q1 | $9K | Hold |
9
| – | – | ﹤0.01% | 5715 |
|
|
2015
Q4 | $8K | Hold |
9
| – | – | ﹤0.01% | 5785 |
|
|
2015
Q3 | $19K | Sell |
9
-1
| -10% | -$2.57K | ﹤0.01% | 5555 |
|
|
2015
Q2 | $32K | Hold |
10
| – | – | ﹤0.01% | 5456 |
|
|
2015
Q1 | $50K | Hold |
10
| – | – | ﹤0.01% | 5005 |
|
|
2014
Q4 | $40K | Hold |
10
| – | – | ﹤0.01% | 5097 |
|
|
2014
Q3 | $38K | Buy |
10
+2
| +25% | +$9.84K | ﹤0.01% | 5033 |
|
|
2014
Q2 | $35K | Buy |
8
+7
| +700% | +$27.2K | ﹤0.01% | 5104 |
|
|
2014
Q1 | $3K | Buy |
+1
| New | +$5.92K | ﹤0.01% | 5620 |
|
|
2013
Q4 | – | Hold |
0
| – | – | – | 5526 |
|
Other funds holding ATOS
VCM
VFT
Wells Fargo's ATOS Position: Q1 2026 in Review
Wells Fargo increased its Atossa Therapeutics (ATOS) stake by 4,833% in Q1 2026, buying an estimated $1.84K and bringing the position to 296 shares worth $1.56K. The position accounts for ﹤0.01% of the portfolio, ranked #6280.
Wells Fargo first reported a position in ATOS in Q1 2014 and has held it in 43 quarters since. The position peaked at $105K in Q4 2021. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.
- Wells Fargo held 296 shares of Atossa Therapeutics worth $1.56K as of Q1 2026.
- Wells Fargo bought 290 Atossa Therapeutics shares in Q1 2026, an estimated $1.84K.
- Atossa Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6280 holding.
- Wells Fargo first reported a position in Atossa Therapeutics in Q1 2014 and has held it in 43 quarters since.
- Wells Fargo's Atossa Therapeutics position peaked at $105K in Q4 2021.
- 33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.